Chronic HBV infection results in >1 million deaths per year from cirrhosis and liver cancer. No known cure for chronic HBV exists, due in part to the continued presence of transcriptionally active DNA in the nucleus that is not directly targeted by current antiviral therapies. A coordinated approach is urgently needed to advance an HBV cure worldwide, such as those established in the HIV field. We propose the establishment of an International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) to facilitate the formation of international working groups on HBV virology, immunology, innovative tools and clinical trials: to promote awareness and education as well as to drive changes in government policy and ensure funds are channelled to HBV cure research and drug development. With the ICE-HBV in place, it should be possible to enable a HBV cure within the next decade.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212–2219 (2012).
Zeisel, M. B. et al. Towards an HBV cure: state-of-the-art and unresolved questions — report of the ANRS workshop on HBV cure. Gut 64, 1314–1326 (2015).
Deeks, S. G. et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607–614 (2012).
Anderson, J. L., Fromentin, R., Corbelli, G. M., Ostergaard, L. & Ross, A. L. Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium. AIDS Res. Hum. Retroviruses 31, 36–44 (2014).
Lo, S. Sharon Lewin: guiding us towards a cure for HIV. Lancet 384, 223 (2014).
Lewin, S. R., Deeks, S. G. & Barre-Sinoussi, F. Towards a cure for HIV — are we making progress? Lancet 384, 209–211 (2014).
Purcell, D. F., Elliott, J. H., Ross, A. L. & Frater, J. Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 10, 134 (2013).
Deeks, S. G. & Barre-Sinoussi, F. Public health: towards a cure for HIV. Nature 487, 293–294 (2012).
Jefferys, R. J. Workshop report: towards a cure: HIV reservoirs and strategies to control them. J. Int. AIDS Soc. 13 (Suppl. 3), I1 (2010).
Gish, R., Jia, J. D., Locarnini, S. & Zoulim, F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect. Dis. 12, 341–353 (2012).
Belloni, L. et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 122, 529–537 (2012).
Maini, M. K. & Peppa, D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front. Immunol. 4, 57 (2013).
Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221–1228 (2014).
Kim, B. K., Revill, P. A. & Ahn, S. H. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir. Ther. 16, 1169–1186 (2011).
Lampertico, P. & Liaw, Y. F. New perspectives in the therapy of chronic hepatitis B. Gut 61 (Suppl. 1), i18–i24 (2012).
Sung, J. J., Tsoi, K. K., Wong, V. W., Li, K. C. & Chan, H. L. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 28, 1067–1077 (2008).
Seto, W. K. et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 58, 923–931 (2013).
Marcellin, P. et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J. Hepatol. 61, 1228–1237 (2014).
Lai, C. L. & Yuen, M. F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57, 399–408 (2013).
Arends, P. et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 64, 1289–1295 (2015).
Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98–107 (2013).
Kim, W. R. et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121, 3631–3638 (2015).
Mozessohn, L., Chan, K. K., Feld, J. J. & Hicks, L. K. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J. Viral Hepat. 22, 842–849 (2015).
Chen, G. D., Gu, J. L., Qiu, J. & Chen, L. Z. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Transpl. Infect. Dis. 15, 300–305 (2013).
Seto, W. K. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 32, 3736–3743 (2014).
Kusumoto, S. et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin. Infect. Dis. 61, 719–729 (2015).
Tseng, T. C. et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142, 1140–1149. e3; quiz e13–e14 (2012).
Lu, H. K. et al. Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. PLoS ONE 9, e113341 (2014).
Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
Koniger, C. et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc. Natl Acad. Sci. USA 111, E4244–E4253 (2014).
Blumberg, B. S., Alter, H. J. & Visnich, S. A 'new' antigen in leukemia sera. JAMA 191, 541–546 (1965).
Urban, S., Bartenschlager, R., Kubitz, R. & Zoulim, F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147, 48–64 (2014).
Volz, T. et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 58, 861–867 (2013).
Watashi, K. et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59, 1726–1737 (2014).
Kaneko, M. et al. A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide. J. Virol. 89, 11945–11953 (2015).
Levrero, M. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581–592 (2009).
Pollicino, T. et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130, 823–837 (2006).
Benhenda, S. et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J. Virol. 87, 4360–4371 (2013).
Belloni, L. et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA 106, 19975–19979 (2009).
Liu, F. et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 9, e1003613 (2013).
Topberger, P. et al. Mapping of histone modifications in episomal HBV cccDNA uncovers unusual chromatic organization amenable to epigenetic manipulation. Proc. Natl Acad. Sci. USA 112, E5715–E5724 (2013).
Zoulim, F. & Mason, W. S. Reasons to consider earlier treatment of chronic HBV infections. Gut 61, 333–336 (2012).
Bourne, C. et al. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J. Virol. 82, 10262–10270 (2008).
Belloni, L. et al. HAPS hepatitis B virus (HBV) capsid inhibitors prevent HBC interaction with the viral minichromosome and selected host cells to inhibit transcription and affect cccDNA stability. Dig. Liver Dis. 46, e9 (2014).
Wynne, S. A., Crowther, R. A. & Leslie, A. G. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3, 771–780 (1999).
Katen, S. P., Tan, Z., Chirapu, S. R., Finn, M. G. & Zlotnick, A. Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure 21, 1406–1416 (2013).
Billioud, G., Pichoud, C., Puerstinger, G., Neyts, J. & Zoulim, F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 92, 271–276 (2011).
Delaney, W. E. 4th et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 46, 3057–3060 (2002).
Deres, K. et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299, 893–896 (2003).
King, R. W. et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (–)β-l-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 42, 3179–3186 (1998).
Leupin, O., Bontron, S., Schaeffer, C. & Strubin, M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J. Virol. 79, 4238–4245 (2005).
Decorsière, A. et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature http://dx.doi.org/.10.1038/nature17170 (2016).
Wooddell, C. I. et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973–985 (2013).
Yuen, M. F. et al. Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B infection. Hepatology 60 (Suppl. 1), 1280A (2014).
Bloom, K., Ely, A., Mussolino, C., Cathomen, T. & Arbuthnot, P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol. Ther. 21, 1889–1897 (2013).
Seeger, C. & Sohn, J. A. Targeting hepatitis B virus with CRISPR/Cas9. Mol. Ther. Nucleic Acids 3, e216 (2014).
Lin, S. R. et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids 3, e186 (2014).
Zoulim, F. & Locarnini, S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 33 (Suppl. 1), 116–124 (2013).
Zoutendijk, R., Hansen, B. E., van Vuuren, A. J., Boucher, C. A. & Janssen, H. L. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J. Infect. Dis. 204, 415–418 (2011).
Chevaliez, S., Hezode, C., Bahrami, S., Grare, M. & Pawlotsky, J. M. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J. Hepatol. 58, 676–683 (2013).
Hadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D. & Hadziyannis, E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143, 629–636. e1 (2012).
Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101, 6669–6674 (2004).
Fisicaro, P. et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974–982 (2009).
Hosel, M. et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50, 1773–1782 (2009).
Lucifora, J. et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51, 63–72 (2010).
Luangsay, S. et al. Expression and Functionality of Toll- and RIG-like receptors in HepaRG Cells. J. Hepatol. 63, 1077–1085 (2015).
Luangsay, S. et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J. Hepatol. 63, 1314–1322 (2015).
Lang, T. et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J. Hepatol. 55, 762–769 (2011).
Visvanathan, K. et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45, 102–110 (2007).
Wilson, R. et al. The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes. J. Viral Hepat. 18, e499–e507 (2011).
Jegaskanda, S. et al. Down-regulation of IL-18 mediated cell signalling and IFN-gamma expression by the hepatitis B virus e antigen. J. Virol. 88, 10412–10420 (2014).
Visvanathan, K. et al. Impaired Toll-like receptor expression in chronic hepatits B: implications for pathogenesis and therapy. Hepatology 38, 138A (2004).
Xia, Y. et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150, 194–205 (2016).
Fosdick, A. et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J. Pharmacol. Exp. Ther. 348, 96–105 (2014).
Menne, S. et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J. Hepatol. 62, 1237–1247 (2015).
Wang, Y. et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice. Int. J. Infect. Dis. 29, 31–36 (2014).
US National Library of Medicine. ClinicalTrials.gov [online], (2015)
US National Library of Medicine. ClinicalTrials.gov [online], (2012)
US National Library of Medicine. ClinicalTrials.gov [online], (2015)
Huang, L. R. et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat. Immunol. 14, 574–583 (2013).
Protzer, U., Maini, M. K. & Knolle, P. A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 12, 201–213 (2012).
Bertoletti, A. & Gehring, A. J. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog. 9, e1003784 (2013).
Milich, D. R. et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl Acad. Sci. USA 87, 6599–6603 (1990).
Hong, M. et al. Trained immunity in newborn infants of HBV-infected mothers. Nat. Commun. 6, 6588 (2015).
Kennedy, P. T. et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143, 637–645 (2012).
Maini, M. K. & Schurich, A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J. Hepatol. 52, 616–619 (2010).
Pallett, L. J. et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat. Med. 21, 591–600 (2015).
Fontaine, H. et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial — ANRS HB02 VAC-ADN. Gut 64, 139–147 (2015).
Seto, W. K. et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin. Microbiol. Infect. 20, 1173–1180 (2014).
Wong, D. K. et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J. Clin. Microbiol. 45, 3942–3947 (2007).
Tu, T. et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J. Viral Hepat. 22, 737–753 (2015).
Mason, W. S., Liu, C., Aldrich, C. E., Litwin, S. & Yeh, M. M. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J. Virol. 84, 8308–8315 (2010).
Hughes, S. A., Wedemeyer, H. & Harrison, P. M. Hepatitis delta virus. Lancet 378, 73–85 (2011).
Fattovich, G. et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 46, 420–426 (2000).
Alvarado-Mora, M. V., Locarnini, S., Rizzetto, M. & Pinho, J. R. An update on HDV: virology, pathogenesis and treatment. Antivir. Ther. 18, 541–548 (2013).
Lampertico, P., Maini, M. & Papatheodoridis, G. Optimal management of hepatitis B virus infection — EASL Special Conference. J. Hepatol. 63, 1238–1253 (2015).
Gunsar, F. Treatment of delta hepatitis. Expert Rev. Anti Infect. Ther. 11, 489–498 (2013).
Heidrich, B. et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60, 87–97 (2014).
Scholtes, C., Kumar, R. & Zoulim, F. Can we predict sustained virologic response to interferon α therapy in patients with chronic hepatitis delta virus infection? Clin. Gastroenterol. Hepatol. 13, 2350–2352 (2015).
Wedemeyer, H. et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N. Engl. J. Med. 364, 322–331 (2011).
Bogomolov, P., Voronkova, N., Allweiss, L. 3rd & Urban, S. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology 60, 1267A–1290A (2014).
Bordier, B. B. et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 112, 407–414 (2003).
Bordier, B. B. et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J. Virol. 76, 10465–10472 (2002).
Koh, C. et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect. Dis. 15, 1167–1174 (2015).
Hepatitis B Foundation. 2015 International meeting molecular biology of hepatitis B viruses [online], (2015).
Lucifora, J. et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. 55, 996–1003 (2011).
Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).
Wong, D. K. et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin. Gastroenterol. Hepatol. 11, 1004–1010. e1 (2013).
Fisicaro, P. et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682–693. e4 (2010).
Fried, M. W. et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47, 428–434 (2008).
Lim, L. Y. et al. Mapping the HBsAg immune phenotype to predict HBsAg loss or decline in chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy. Hepatology 60 (Suppl. 1), 980A (2014).
Ganes, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).
Bertoletti, A. & Kennedy, P. T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell. Mol. Immunol. 12, 258–263 (2015).
Knolle, P. A. & Thimme, R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146, 1193–1207 (2014).
P.R. received research funding from Gilead Sciences. B.T. declares no competing interests. S.L. received research funding from Arrowhead and Gilead Sciences and consultancies from Arrowhead, Gilead Sciences and Janssen. F.Z. received research grants from Assembly Bioscience, Gilead Sciences, Janssen, Novira and Roche, and consultancies from Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Novira, Roche and Tekmira.
About this article
Cite this article
Revill, P., Testoni, B., Locarnini, S. et al. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol 13, 239–248 (2016). https://doi.org/10.1038/nrgastro.2016.7
Scientific Reports (2021)
Nature Reviews Gastroenterology & Hepatology (2020)
Modulation of hepatitis B virus infection by epidermal growth factor secreted from liver sinusoidal endothelial cells
Scientific Reports (2020)
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation
Cellular Oncology (2020)
Current Hepatology Reports (2020)